



**Laboratory
Services**

2017-2019

TEST UPDATES

Beth Marcotte, Lead Microbiology Technologist 802.747.1782

Alma Vazquez, Lab Manager 802.772.1989

Brian Cameron, Outreach Coordinator 802.747.1759

Keith LeBlanc, Lab Director 802.747.1825

Heather Bixler, MD, Medical Director 802.747.1786

Infectious Disease 802.747.3700

Date: May 21, 2020

To: Medical Staff Office Managers Nurse Managers
Laboratory Staff

Subject: 2019 Antimicrobial Susceptibility Trend Report

We are pleased to once again provide separate antibiograms for our outpatient and inpatient providers. If you require further assistance, please contact Microbiology or our Infectious Disease Department.

Susceptibility Trend Notes:

- Numbers reported are percent (%) of organisms susceptible to antibiotic.
- Maximum number (#) of strains tested is listed in ()
- ↑ Demonstrates a greater than (>) 5% increase in susceptibility from previous year
- ↓ Demonstrates a greater than (>) 5% decrease in susceptibility from previous year



2019 Antibiogram Inpatient Providers (January-December)

Relative Cost Per Day PO/IV ¹	\$\$	\$	\$	\$	\$	\$	\$	\$	\$\$	\$\$	\$	\$\$	\$\$	\$\$ IV	\$	\$
Gram Negative Organisms Legend: • Susceptible Reported as % • (Maximum # strains tested) ↑ > 5% increase in Susceptibility from Previous Year ↓ > 5% decrease in Susceptibility from Previous Year	Amikacin	Ampicillin	Amp/sulbactam	Cefazolin ²	Cefoxitin	Ceftazidime	Ceftriaxone	Ciprofloxacin	Gentamicin	Meropenem	Levofloxacin	Pip/Tazobactam	Tobramycin	Trimethoprim/sulfa	Nitrofurantoin Urinary Tract Infections only	Cefepime ³
<i>Escherichia coli</i> (1875)	100	63	69	93 ²	93	98	95	89	94	100	89	98	95	84	97	68/94 ^{3,4}
<i>Enterobacter species</i> (153)	100	-	-	0	1	90	88	99	99	99	99	88	100	92	32↑	-
<i>Klebsiella species</i> (444)	100	0	80	90 ²	96	95	91	92	97	100	93	94	93	88	44	22/47 ^{3,4}
<i>Proteus species</i> (146)	100	86	95	99 ²	98	99	99	82↓	97	100	85	99	97	87	0	-
<i>Pseudomonas aeruginosa</i> (157)	99	-	-	-	-	97	-	93	97	99	87	100	100	-	-	97

Relative Cost Per Day PO/IV ¹	\$	\$	\$	\$	\$	\$\$	\$	\$\$	\$	\$	\$	\$	\$	\$\$ IV	\$\$	\$
Gram Positive Organisms Legend: • Susceptible Reported as % • (Maximum # strains tested) ↑ > 5% increase in Susceptibility from Previous Year ↓ > 5% decrease in Susceptibility from Previous Year	Ampicillin	Ceftriaxone Non-meningitis	Ceftriaxone Meningitis	Clindamycin	Erythromycin	Gentamicin	Levofloxacin	Linezolid	Oxacillin ⁵	Penicillin	Penicillin Non-meningitis	Penicillin Meningitis	Tetracycline	Trimethoprim/sulfa	Vancomycin	Nitrofurantoin Urinary Tract Infections only
<i>Staphylococcus aureus</i> (675)	-	-	-	78	48	99	77	100	68↑	0	-	-	94	97	100	100
Methicillin Resistant <i>Staphylococcus aureus</i> ⁶ (153)	-	-	-	78	14	99	45	100	0	0	-	-	94	97	100	9/9
<i>Staphylococcus coagulase negative</i> (173)	-	-	-	65↓	45↓	92	69↓	100	60	0	-	-	83↓	69↓	100	100
<i>Enterococcus faecalis</i> (220)	100	-	-	-	-	-	79	100	-	100	-	-	-	-	99	99
<i>Enterococcus faecium</i> (35)	11↓	-	-	-	-	-	6↓	100	-	11↓	-	-	-	-	49	17
<i>Streptococcus pneumoniae</i> (51)	-	96	80	75	45	-	100	100	-	-	96	67	77	-	-	-
<i>Streptococcus agalactiae</i> (Group B) (35)	100	-	-	34	29	-	100	100	-	100	-	-	-	-	100	-

- Relative Total Cost per Day PO/IV for Treatment: Green = Least expense, Red = Most expense
- Cannot differentiate Cefazolin Susceptible from Intermediate categories by testing method on non urinary tract specimens. Results valid only when used as therapy for uncomplicated UTI for *Escherichia coli*, *Klebsiella pneumoniae* or *Proteus mirabilis*.
- Cefepime tested by manual method on ESBL positive only (*Escherichia coli* and *Klebsiella pneumoniae*).
- Reported as actual number of isolates susceptible and includes susceptible dose dependent (SDD).
- Oxacillin is tested as a surrogate for methicillin and nafcillin
- Data collection for Methicillin Resistant *Staphylococcus aureus* began 4/9/2019.